GDS Wealth Management Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

GDS Wealth Management boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,529 shares of the medical research company’s stock after purchasing an additional 4,636 shares during the quarter. GDS Wealth Management’s holdings in IQVIA were worth $11,698,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Capital Performance Advisors LLP acquired a new position in IQVIA in the third quarter valued at $27,000. Park Place Capital Corp acquired a new position in IQVIA in the 3rd quarter valued at about $28,000. Synergy Asset Management LLC purchased a new stake in IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC lifted its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the period. Finally, Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE IQV opened at $199.34 on Tuesday. The company has a market capitalization of $36.18 billion, a price-to-earnings ratio of 26.16, a PEG ratio of 2.15 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The business has a 50-day moving average of $200.41 and a 200-day moving average of $220.32.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IQV shares. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Finally, Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $254.53.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.